Company profile

Ronnie Morris
Fiscal year end
Former names
Champions Biotechnology, Inc., Champions Sports Inc
IRS number

CSBR stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


28 Jul 20
13 Aug 20
30 Apr 21


Company financial data Financial data

Quarter (USD) Apr 20 Jan 20 Oct 19 Jul 19
Revenue 9.01M 7.63M 6.74M
Net income -2.07M 407K 307K -641K
Diluted EPS -0.18 0.03 0.02 -0.06
Net profit margin 4.52% 4.03% -9.51%
Operating income -1.91M 433K 291K -614K
Net change in cash 5.02M 498K 582K -998K
Cash on hand 8.3M 3.28M 2.78M 2.2M
Cost of revenue 4.33M 3.88M 3.75M
Annual (USD) Apr 20 Apr 19 Apr 18 Apr 17
Revenue 32.12M 2.9M 20.24M 15.41M
Net income -2M 128K -1.48M -6.88M
Diluted EPS -0.17 0.01 -0.13 -0.64
Net profit margin -6.23% 4.41% -7.29% -44.67%
Operating income -1.8M 270K -1.35M -6.81M
Net change in cash 5.1M 2.34M -2.44M 710K
Cash on hand 8.3M 3.2M 856K 3.3M

Financial data from company earnings reports

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
26 Mar 20 Mendelson Daniel Newman Common Stock Buy Aquire P No 5.89 300 1.77K 58,746
26 Mar 20 Mendelson Daniel Newman Common Stock Buy Aquire P No 5.9 700 4.13K 58,446
26 Mar 20 Mendelson Daniel Newman Common Stock Buy Aquire P No 5.97 100 597 57,746
26 Mar 20 Mendelson Daniel Newman Common Stock Buy Aquire P No 5.99 100 599 57,646
26 Mar 20 Mendelson Daniel Newman Common Stock Buy Aquire P No 6 20 120 57,546
24 Mar 20 Morris Ronnie Common Stock Sell Dispose S No 5.25 75 393.75 837,168
24 Mar 20 Mendelson Daniel Newman Common Stock Buy Aquire P No 5.5 26 143 57,526
20 Mar 20 Morris Ronnie Common Stock Buy Aquire P No 4.75 75 356.25 837,243
11 Mar 20 Battery Ventures IX Common Stock Aquire X No 5.76 286,458 1.65M 2,421,673
11 Mar 20 Battery Ventures IX Common Stock Aquire X No 4.8 123,333 592K 2,135,215
54.4% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 34 35 -2.9%
Opened positions 3 5 -40.0%
Closed positions 4 5 -20.0%
Increased positions 10 9 +11.1%
Reduced positions 11 11
13F shares
Current Prev Q Change
Total value 47.79M 47.79M +0.0%
Total shares 6.47M 5.74M +12.7%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Battery Partners IX 2.42M $17.92M +20.4%
NEA Management 1.71M $12.68M +9.7%
Cowen Prime Services 299.4K $2.22M +95.0%
Vanguard 286.83K $2.12M +8.2%
Tocqueville Asset Management 252.46K $1.87M +23.4%
Cadence Capital Management 222.31K $1.65M -5.1%
Renaissance Technologies 177.05K $1.31M -5.5%
Essex Investment Management 170.06K $1.26M -2.3%
BLK BlackRock 147.95K $1.1M +4.5%
Dimensional Fund Advisors 133.25K $986K 0.0%
Largest transactions
Shares Bought/sold Change
Battery Partners IX 2.42M +409.79K +20.4%
NEA Management 1.71M +151.22K +9.7%
Cowen Prime Services 299.4K +145.9K +95.0%
Tocqueville Asset Management 252.46K +47.89K +23.4%
WFC Wells Fargo & Company 37 -24.96K -99.9%
Globeflex Capital L P 23.29K +23.29K NEW
Vanguard 286.83K +21.64K +8.2%
Perkins Capital Management 20.5K -17.5K -46.1%
Millrace Asset 82.5K -17.05K -17.1%
Cadence Capital Management 222.31K -11.83K -5.1%

Financial report summary

Cancer Genetics
  • We historically incurred losses from operating activities, may require significant capital and may never achieve sustained profitability.
  • We may incur greater costs than anticipated, which could result in sustained losses.
  • We may not be able to implement our business strategies which could impair our ability to continue operations.
  • Our business could be adversely impacted by changes in FDA’s regulatory oversight of laboratory-developed tests such as our POS services that are currently under consideration or by other changes in the regulatory requirements applicable to our POS services imposed by the FDA or regulatory authorities in other countries in which our services are provided.
  • Our laboratories are subject to regulation and licensure requirements, and the healthcare industry is highly regulated; we may face substantial penalties, and our business activities may be impacted, if we fail to comply.
  • If our laboratory facilities are damaged or destroyed, or we have a dispute with one of our landlords, our business would be negatively affected.
  • Any health crisis impacting our colony of laboratory mice could have a negative impact on our business.
  • We have limited experience marketing and selling our products and may need to rely on third parties to successfully market and sell our products and generate revenues.
  • We will continue to be dependent upon key employees.
  • Because our industry is very competitive and many of our competitors have substantially greater capital resources and more experience in research and development, we may not succeed in selling or increasing sales of our products and technologies.
  • If we are unable to protect our intellectual property, we may not be able to compete as effectively.
  • If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
  • Claims by others that our products infringe their patents or other intellectual property rights could adversely affect our financial condition.
  • Patients are unable to obtain reimbursement from third-party payers for our services, limiting the market acceptance of our services, and as a result we may not achieve significant revenues.
  • TOS studies are subject to cancellation based on changes in customer’s development plans.
  • Our ability to use our net operating loss carry-forwards and certain other tax attributes may be limited.
  • We have a limited market for our common stock, which makes our securities very speculative.
  • Investment in our common stock may be diluted if we issue additional shares in the future.
  • Our stock price is volatile and therefore investors may not be able to sell their common stock at or above the price they paid for it.
  • Certain provisions of our charter and bylaws and of our contractual agreements contain provisions that could delay and discourage takeover attempts and any attempts to replace our current management by shareholders.
  • Our management and three significant stockholders collectively own a substantial majority of our common stock.
  • We have not paid any cash dividends in the past and have no plans to issue cash dividends in the future, which could cause the value of our common stock to have a lower value than other similar companies which do pay cash dividends.
  • If securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they change their recommendations regarding our common stock adversely, the price of our common stock and trading volume could decline.
Content analysis ?
H.S. freshman Avg
New words: absolute, Aid, American, back, budgeting, capacity, CEO, China, closure, Codification, critical, Description, detected, dictated, disease, disruption, embedded, endpoint, epidemic, European, expedient, fourth, genomic, globally, globe, immaterial, implicit, intraperiod, Latin, match, newly, outbreak, outsourced, pandemic, paper, paragraph, pattern, postpone, processed, proclamation, prospective, reassessment, recast, Relief, remotely, replenished, ROU, spread, staffing, strain, submitted, threshold, transparency, unanticipated, unaudited, unchanged, underlying, world, worldwide, worsen, Wuhan
Removed: accrual, aggregate, Baltimore, Black, capitalization, CD, collateral, collect, correlation, created, custody, Cutting, deposit, East, Edge, evaluate, exceeded, exchanged, expertise, fewer, frequently, fulfill, higher, internationally, makeup, maturity, nature, North, participating, reclassified, renewed, repatriation, screen, subtracting, Treadway, unlimited, withdrawal, Wolfe, York